$MBRX

Foster Jonathan P. (Chief Financial Officer) purchased 293,333 shares of Moleculin Biotech, Inc. (MBRX) on 2026-08-03.

PICKER DONALD H (Chief Science Officer) purchased 173,333 shares of Moleculin Biotech, Inc. (MBRX) on 2026-08-03.

Moleculin Biotech reported interim blinded Part A data from its MIRACLE Phase II/III trial of Annamycin plus cytarabine (AnnAraC) in relapsed or refractory AML. In 62 evaluable patients, CR was 24% and CRc 37%. Among 30 prior venetoclax-failure patients, results were in a harder-to-treat group. Part A has 74/90 enrolled, completion expected by Sep 2026, unblinded results Dec 2026-Feb 2027.

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 ex_997517.htm EXHIBIT 10.1 ex_997517.htm Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 31, 2026, between Moleculin Biotech, Inc., a Delaware corporation (the “ Company ”), and each purchaser identi

Moleculin Biotech (NASDAQ:MBRX) priced a $9.3 million public stock offering at $0.75 per share, plus warrants, to fund clinical programs. Shares fell sharply on dilution concerns. In its MIRACLE trial, 62 evaluable patients showed 24% blinded complete remission and 37% composite complete remission. Recruitment reached 74 of 90 planned patients; full data unblinding expected Dec 2026 to Feb 2027.

Moleculin Biotech (MBRX) priced a public offering expected to raise about $9.3 million gross proceeds. It will sell 12.38 million common shares (or pre-funded warrants) plus common warrants for up to 37.13 million shares at $0.75 per share. Net proceeds will fund Annamycin clinical development and working capital. Shares last traded around $0.35, down 65.2%.

Moleculin Biotech (Nasdaq: MBRX) priced a best-efforts public offering of 12,376,667 shares of common stock, or pre-funded warrants in lieu, plus warrants to buy up to 37,130,001 shares. The combined price is $0.75 per share, with warrants exercisable immediately and expiring five years after initial exercise. Net proceeds will fund Annamycin clinical development and working capital; expected close around Aug. 3, 2026.

Moleculin Biotech (Nasdaq: MBRX) said CEO Walter Klemp discussed in a virtual investor segment preliminary unblinded efficacy from the first 45 patients in Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin (naxtarubicin) for relapsed/refractory AML. The company also cited market research on Annamycin’s addressable market and noted interim results are based on a small, non-statistically significant sample.

Moleculin Biotech (Nasdaq: MBRX) reported preliminary unblinded interim results from the first 45 patients in Part A of its Phase 2/3 MIRACLE trial in relapsed/refractory AML. Complete remission (CR) was 43% and 36% for Annamycin dose arms vs 12% control; composite CR (CRc) was 50% and 57% vs 29%. The iDMC said there was a numeric CR trend favoring Annamycin but no statistical significance and recommended continuing; 67/90 Part A patients are enrolled.

Moleculin Biotech (NASDAQ: MBRX) is a clinical-stage pharmaceutical company focused on developing novel small-molecule cancer therapies, particularly targeting acute myeloid leukemia (AML) and solid tumors. The article examines whether its oncology pipeline, featuring lead product Annamycin and other candidates like WP1066, is robust enough to attract investor interest and deliver returns. It highlights the company's asset-light business model, focus on unmet medical needs, and the speculative nature of biotech investments driven by binary trial readouts.